AR and prostate cancer: These altered ASCs were reported to express epithelial markers, such as androgen receptor (AR), prostate-specific antigen (PSA), CK8, and CK5/18, neoplastic features, including tumorigenic markers, such as Ki67, p53, and Ras, and vasculogenic markers, such as Willebrand factor and α-smooth muscle actin, alongside molecular features similar to those of prostate cancer tumor xenografts (Elmageed et al., 2014).